Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | COMT | P21964 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817190 | 1.00 | SLC7A5 (0.38) | SLC7A5DPP4PSMB5COMT | |
| SCHEMBL5515013 | 0.83 | DPP4 (0.38) | DPP4 | |
| SCHEMBL844429 | 0.79 | — | — | |
| SCHEMBL7599670 | 0.79 | SLC7A5 (0.44) | SLC7A5DPP4PSMB5COMT | |
| SCHEMBL9621432 | 0.77 | SLC7A5 (0.45) | SLC7A5DPP4 | |
| SCHEMBL9506655 | 0.77 | SLC7A5 (0.45) | SLC7A5DPP4 | |
| SCHEMBL12286895 | 0.77 | SLC7A5 (0.42) | SLC7A5DPP4PSMB5COMT | |
| SCHEMBL14351292 | 0.77 | TP53 (0.32) | — | |
| SCHEMBL19420430 | 0.77 | SLC7A5 (0.42) | SLC7A5DPP4PSMB5COMT | |
| SCHEMBL8288611 | 0.75 | SLC7A5 (0.41) | SLC7A5DPP4PSMB5COMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | MEDIVIR AB (SE) | 2013-01-03 | — | — | US | disclosed |
| EP-2499120-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | Novadex Pharmaceuticals AB (SE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011056126-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | NOVADEX PHARMACEUTICALS AB (SE) | 2011-05-12 | — | — | WO | disclosed |
| EP-0246187-B1 | 2-PYRIDYL PENEM COMPOUNDS | CIBA-GEIGY AG (CH) | 1992-02-05 | — | — | EP | disclosed |
| US-4826832-A | BACTERICIDES | CIBA-GEIGY CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
| US-4794109-A | 6-hydroxy-lower alkylpenem compounds, pharmaceutical preparations that contain these compounds, and the use of the latter | CIBA-GEIGY CORPORATION (US) | 1988-12-27 | — | — | US | disclosed |
| EP-0275233-A1 | 2-Heterocyclylalkyl-2-penem compounds | CIBA-GEIGY AG (CH) | 1988-07-20 | — | — | EP | disclosed |
| EP-0252885-A1 | Bicyclic thiaaza compounds | CIBA-GEIGY AG (CH) | 1988-01-13 | — | — | EP | disclosed |
| EP-0246187-A2 | 2-Pyridyl penem compounds | CIBA-GEIGY AG (CH) | 1987-11-19 | — | — | EP | disclosed |
| EP-0199675-A1 | Heterocyclic penem compounds | CIBA-GEIGY AG (CH) | 1986-10-29 | — | — | EP | disclosed |
| EP-0148128-A2 | Optically active penem compounds | CIBA-GEIGY AG (CH) | 1985-07-10 | — | — | EP | disclosed |
| EP-0125207-A1 | 2-Tetrazolylpropyl-2-penem derivatives, process for their preparation, pharmaceutical compositions containing them and their use | CIBA-GEIGY AG (CH) | 1984-11-14 | — | — | EP | disclosed |
| EP-0121499-A2 | Cephalosporins, their preparation and pharmaceutical compositions | CIBA-GEIGY AG (CH) | 1984-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | REN, AGTR1, ACE | SLC7A5 1890/4885DPP4 28/4885PSMB5 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.